NDARECTALAEROSOL, METERED
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
CORTIFOAM (hydrocortisone acetate) by Viatris (2) is clinical pharmacology cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. First approved in 1982.
Drug data last refreshed 25m ago · AI intelligence enriched 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORTIFOAM is a metered-dose rectal aerosol containing hydrocortisone acetate, a topical corticosteroid approved in 1982 for adjunctive treatment of ulcerative proctitis. It delivers anti-inflammatory therapy directly to the rectum, with evidence showing penetration approximately 10 centimeters into the rectal tract. The drug reduces inflammation in inflammatory bowel disease affecting the lower colon and rectum.
$0.528MPart D
LOE ApproachingThis product faces imminent loss of exclusivity with modest Medicare spending ($528K in 2023), indicating a small, specialized team focused on retention rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Started Mar 2016
16 enrolled
Healthy
Career Relevance
CORTIFOAM offers limited career growth potential as a declining, specialty product approaching generic competition and market contraction. Roles on this brand typically involve lifecycle management, market defense, and physician engagement rather than launch strategy or market expansion.
Brand Manager
Worked on CORTIFOAM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.